39 results on '"Yu, Huiming"'
Search Results
2. Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study
- Author
-
Du, Rongxu, Fan, Songqing, Yang, Dan, Wang, Xiaobin, Hou, Xia, Zeng, Cheng, Guo, Dan, Tian, Rongrong, Jiang, Leilei, Dong, Xin, Yu, Rong, Yu, Huiming, Zhu, Shuchai, Li, Jie, and Shi, Anhui
- Published
- 2024
- Full Text
- View/download PDF
3. Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study
- Author
-
Du, Rongxu, Fan, Songqing, Wang, Xiaobin, Hou, Xia, Zeng, Cheng, Guo, Dan, Tian, Rongrong, Yang, Dan, Jiang, Leilei, Dong, Xin, Yu, Rong, Yu, Huiming, Li, Dongming, Zhu, Shuchai, Li, Jie, and Shi, Anhui
- Published
- 2022
- Full Text
- View/download PDF
4. Prognostic role of an inflammation scoring system in radical resection of oral squamous cell carcinoma
- Author
-
Wu, Meng, Ye, Pu, Zhang, Wei, Zhu, Hong, and Yu, Huiming
- Published
- 2022
- Full Text
- View/download PDF
5. A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma
- Author
-
Dong, Xin, Deng, Wei, Jiang, Leilei, Yang, Dan, Yu, Huiming, Li, Dongming, Shi, Anhui, Yu, Rong, and Wang, Weihu
- Published
- 2022
- Full Text
- View/download PDF
6. Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis.
- Author
-
Guo, Xiaohong, Wang, Li, Beeraka, Narasimha M, Liu, Chunying, Zhao, Xiang, Zhou, Runze, Yu, Huiming, Fan, Ruitai, and Liu, Junqi
- Subjects
REPORTING of diseases ,RESEARCH ,CEREBRAL dominance ,CONFIDENCE intervals ,DISEASE incidence ,REGRESSION analysis ,CANCER patients ,RESEARCH funding ,RETINOBLASTOMA ,PREDICTION models ,RESIDENTIAL patterns ,STATISTICAL correlation ,OVERALL survival ,PROPORTIONAL hazards models ,SYMPTOMS ,CHILDREN - Abstract
Background Retinoblastoma is the most common intraocular malignant tumor occurring among children, with an incidence rate of 1/15 000. This study built a joinpoint regression model to assess the incidence trend of retinoblastoma from 2004 to 2015 and constructed a nomogram to predict the overall survival (OS) in children. Materials and Methods Patients less than 19 years diagnosed with retinoblastoma from 2004 to 2015 were selected from the SEER database. Joinpoint regression analysis (version 4.9.0.0) was performed to evaluate the trends in retinoblastoma incidence rates from 2004 to 2015. Cox Regression Analysis was applied to investigate prognostic risk factors that influence OS. Results Joinpoint regression revealed that retinoblastoma incidence exhibited no significant increase or decrease from 2004 to 2015. As per the multiple Cox regression, tumor size, laterality, and residence (rural-urban continuum code) were correlated with OS and were used to construct a nomogram. The nomogram exhibited a good C-index of 0.71 (95% CI, 0.63 to 0.79), and the calibration curve for survival probability demonstrated that the predictions corresponded well with actual observations. Conclusions and Relevance A prognostic nomogram integrating the risk factors for retinoblastoma was constructed to provide comparatively accurate individual survival predictions. If validated, this type of assessment could be used to guide therapy in patients with retinoblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Ground-based calibration and characterization of the HE detectors for Insight-HXMT
- Author
-
Li, XuFang, Liu, CongZhan, Chang, Zhi, Zhang, YiFei, Li, XiaoBo, Gao, He, Li, ZhengWei, Lu, XueFeng, Zhou, Xu, Zhang, AiMei, Zhang, Tong, Lu, FangJun, Xu, YuPeng, Zhang, ShuangNan, Li, TiPei, Wu, Mei, Zhang, Shu, Liu, HongWei, Zhang, Fan, Song, LiMing, Jin, YongJie, Yu, HuiMing, Zhang, Zhao, Fu, MinXue, Chen, YiBao, Deng, JingKang, Shang, RenCheng, Liu, GuoQing, Wu, JinJie, Liu, HaoRan, Liang, JunCheng, and Qiu, XiangPing
- Published
- 2019
- Full Text
- View/download PDF
8. Faculty Workshops for Teaching Information Assurance through Hands-On Exercises and Case Studies
- Author
-
Yuan, Xiaohong, Williams, Kenneth, Yu, Huiming, Rorrer, Audrey, Chu, Bei-Tseng, Yang, Li, Winters, Kathy, and Kizza, Joseph
- Abstract
Though many Information Assurance (IA) educators agree that hands-on exercises and case studies improve student learning, hands-on exercises and case studies are not widely adopted due to the time needed to develop them and integrate them into curricula. Under the support of the National Science Foundation (NSF) Scholarship for Service program, we organized two faculty development workshops to disseminate effective hands-on exercises and case studies developed through multiple previous and ongoing grants. To develop faculty expertise in IA, the workshop covered a wide range of IA topics. This paper describes the hands-on exercises and case studies we disseminated through the workshops and reports our experiences of holding the faculty summer workshops. The evaluation results show that workshop participants demonstrated high levels of satisfaction with knowledge and skills gained in both the 2012 and 2013 workshops. Workshop participants also reported use of hands-on lab and case study materials in our follow-up survey and interviews. The workshops provided a valuable opportunity for IA educators to communicate and form collaborations in teaching and research in IA.
- Published
- 2017
9. MiR-let-7e inhibits invasion and magration and regulates HMGB1 expression in papillary thyroid carcinoma
- Author
-
Ding, Chao, Yu, Huiming, Shi, Chenlei, Shi, Tiefeng, Qin, Huadong, and Cui, Yunfu
- Published
- 2019
- Full Text
- View/download PDF
10. Magnetic resonance (MR) imaging for tumor staging and definition of tumor volumes on radiation treatment planning in nonsmall cell lung cancer: A prospective radiographic cohort study of single center clinical outcome
- Author
-
Zhao, Dan, Hu, Qiaoqiao, Qi, Liping, Wang, Juan, Wu, Hao, Zhu, Guangying, and Yu, Huiming
- Published
- 2017
- Full Text
- View/download PDF
11. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
- Author
-
Liu, Meng, Sjogren, Anna-Karin M., Karlsson, Christin, Ibrahim, Mohamed X., Andersson, Karin M. E., Olofsson, Frida J., Wahlstrom, Annika M., Dalin, Martin, Yu, Huiming, Chen, Zhenggang, Yang, Shao H., Young, Stephen G., Bergo, Martin O., and Jacks, Tyler
- Published
- 2010
12. Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.
- Author
-
Yu, Chengqi, Jiang, Leilei, Yang, Dan, Dong, Xin, Yu, Rong, and Yu, Huiming
- Subjects
NON-small-cell lung carcinoma ,PROGRAMMED cell death 1 receptors ,SQUAMOUS cell carcinoma - Abstract
Purpose: As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial. Patients and Methods: From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan–Meier method. Results: 57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1– 3, one drug-related death was noted. Conclusion: The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Testing lncRNAs signature as clinical stage–related prognostic markers in gastric cancer progression using TCGA database.
- Author
-
Beeraka, Narasimha M, Gu, Hao, Xue, Nannan, Liu, Yang, Yu, Huiming, Liu, Junqi, Chen, Kuo, Nikolenko, Vladimir N, and Fan, Ruitai
- Published
- 2022
- Full Text
- View/download PDF
14. Destination Driven Motion Planning via Obstacle Motion Prediction and Multi-State Path Repair
- Author
-
Yu, Huiming and Su, Tong
- Published
- 2003
- Full Text
- View/download PDF
15. Publishing education of China faces the challenge of development
- Author
-
Yu, Huiming
- Published
- 2001
- Full Text
- View/download PDF
16. Aimy: An autonomous mobile robot navigation in unknown environment with infrared detector system
- Author
-
Yu, Huiming and Malik, Raashid
- Published
- 1995
- Full Text
- View/download PDF
17. Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT.
- Author
-
Shen, Junyue, Yang, Dan, Chen, Mailin, Jiang, Leilei, Dong, Xin, Li, Dongming, Yu, Rong, Yu, Huiming, and Shi, Anhui
- Subjects
NON-small-cell lung carcinoma ,VOLUMETRIC-modulated arc therapy ,STEREOTACTIC radiotherapy ,OVERALL survival ,CHEMORADIOTHERAPY ,PROGRESSION-free survival - Abstract
Background: Hypofractionated radiotherapy (HypoRT) has been used to pursue an alternative treatment regimen for patients with non-small-cell lung cancer (NSCLC) who are not eligible for stereotactic ablative radiotherapy (SABR), surgery or concurrent chemoradiotherapy (CCRT) and has shown good local control and safety. We analyzed the feasibility of using volumetric-modulated arc radiotherapy (VMAT) with the simultaneous integrated boost (SIB) technique to achieve high local control with few treatment-related toxicities. Patients and Methods: A total of 55 patients with stage I-IV NSCLC who were not candidates for SABR, surgery or CCRT were included in the present study. All patients received a prescribed dose of 60 to 66 Gy in 15 fractions. Local progression-free survival (LPFS), PFS, overall survival (OS), and toxicities were retrospectively analyzed. Results: Thirty-three patients (60.0%) had stage IV or recurrent disease in this study. The median follow-up time was 8 months (interquartile range: 5.0-16.3 months). The 1-year and 2-year OS rates were 84.3% and 69.9%, and the 1-year and 2-year LPFS rates were 91.0% and 63.0%. The median OS (mOS) and median LPFS (mLPFS) were not reached, and median PFS (mPFS) was 15 months. Twenty-eight (51.9%) patients had disease progression at the time of analysis. Of these, 7 (13.0%), 7 (13.0%) and 21 (38.9%) had local recurrence, locoregional failure and distant metastasis, respectively. All cases of local recurrence were found within the SIB region. Four patients had grade 2-3 pneumonitis, and 8 patients had grade 2-3 esophagitis. Patients with grade 2-3 esophagitis had significantly higher maximum dose and dose to 5 cm
3 volume to esophagus than those with grade 0-1 esophagitis. No grade 4 or higher toxicity was observed. Conclusion: The 60 to 66 Gy in 15 fractions RT regimen provides favorable local control and survival with well-tolerated toxicities. Hypofractionated VMAT+SIB is an alternative treatment option for patients with NSCLC who cannot tolerate standard definitive therapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers.
- Author
-
Sui, Xin, Jiang, Leilei, Teng, Huajing, Mi, Lan, Li, Bo, Shi, Anhui, Yu, Rong, Li, Dongming, Dong, Xin, Yang, Dan, Yu, Huiming, and Wang, Weihu
- Subjects
NON-small-cell lung carcinoma ,TREATMENT effectiveness ,CANCER patients ,CHEMORADIOTHERAPY ,CD54 antigen - Abstract
Purpose: To identify cytokines in plasma that may predict objective response and progression-free survival (PFS) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with chemoradiotherapy. Materials and Methods: From April 2016 to May 2017, thirty-one patients with locally advanced inoperable/unresectable NSCLC were included, and treated with concurrent chemoradiotherapy (CCRT). No immune checkpoint inhibitors were administered after CCRT. Plasma from each patient was collected before radiotherapy, and 25 cytokines in the plasma were measured by Luminex or U-PLEX assays. Logistic regression and COX regression were performed to identify the predictive factors for objective response and PFS, respectively. Kaplan-Meier survival analysis was used to compare the PFS between the groups. Results: High levels of IL-13 and TNF-α, and low levels of ICAM-1, IFN-γ, and soluble PD-L1 (sPD-L1) were significantly associated with objective response (P < 0.05). High levels of IL-8, CCL5, and CXCL3 also showed a trend toward association with objective response (P < 0.1). The combination of cytokines (IL-8 and ICAM-1, or TNF-α and sPD-L1) improved predictive accuracy. Univariate analysis identified IL-8 and ICAM-1 as potential markers to predict PFS. Multivariate analysis suggested that high level of IL-8 (P =0.010) and low level of ICAM-1 (P =0.011) correlated significantly with a longer PFS. Conclusion: IL-8 and ICAM-1 in plasma have the potential to predict objective response and PFS in patients with locally advanced NSCLC underwent chemoradiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Hybrid evolutionary motion planning using follow boundary repair for mobile robots
- Author
-
Yu, Huiming, Chi, Chia-Jung, Su, Tong, and Bi, Qiang
- Published
- 2001
- Full Text
- View/download PDF
20. Mapping of Regional Failures After Definitive Radiotherapy in Patients with Locally Advanced Cervical Esophageal Carcinoma.
- Author
-
Zhao, Dan, Zheng, Baomin, Xiao, Shaowen, Liu, Weixin, Xu, Xiaolong, Yu, Huiming, Sun, Yan, and Wang, Weihu
- Subjects
SQUAMOUS cell carcinoma ,PROGRESSION-free survival ,CARCINOMA ,RADIOTHERAPY ,COMPLEX regional pain syndromes ,MEDICAL records - Abstract
Purpose: This study aimed to retrospectively analyze the failure patterns and clinical outcomes in patients with locally advanced cervical esophageal carcinoma (CEC) after definitive radiotherapy (RT), and illustrate the mapping of regional failures. Patients and Methods: We reviewed 82 patients with CEC confirmed as squamous cell carcinoma who had completed definitive RT from August 2008 to December 2017. Data on clinical characteristics were collected from the medical records system. Patterns of treatment failures and the survival follow-up were analyzed. Results: The median age was 58 (38– 78) years. In 37 patients, the lesions were limited to the cervical esophagus, while in the remaining 45 patients, the disease got beyond the cervical esophagus (pharynx or thoracic esophagus involved). While 10 patients had stage Ⅱ disease, 72 had stage III disease. The completed median dose for 95% PGTV and 95% PTV was 66 Gy and 58 Gy. While the median follow-up was 27.6 months, the median progression-free survival (PFS) and overall survival (OS) was 16.1 and 28.3 months, respectively. The 3-year PFS and OS was 30.3% and 45.3%, respectively. Treatment failures were reported in 55 patients, of which 22, 8, 7, 9, 2, 3, and 4 patients had developed local, regional, distant, local-regional, regional-distant, local-distant and local-regional-distant failure, respectively. Of the 41 relapsed nodal sites, 28 were located "in-field" whereas 1 was "marginal" and 12 were "out-field". The most frequent regional relapses were at level VIb, IV and the upper-middle mediastinum. Conclusion: Regional recurrences focused on lower neck and upper-middle mediastinum, and mainly "in-field", after definitive RT in patients with CEC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer.
- Author
-
Yang, Dan, Cui, Jianing, Zhao, Jun, You, Jing, Yu, Rong, Yu, Huiming, Jiang, Leilei, Li, Dongming, Xu, Bo, and Shi, Anhui
- Subjects
BRONCHI ,CANCER patients ,HEART ,LUNG cancer ,EVALUATION of medical care ,PATIENT safety ,RADIATION doses ,RADIOTHERAPY ,SURVIVAL ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,EVALUATION - Abstract
Background: There is no consensus on the definition or recommended radiotherapy treatment of ultracentral non‐small cell lung cancer (NSCLC). Here, we report our institution's experience in treating ultracentral lung cancer patients with stereotactic ablative radiotherapy (SABR) of 60 Gy in eight fractions. Methods: We retrospectively reviewed the outcomes of 21 ultracentral NSCLC patients treated with 60 Gy SABR in eight fractions. We defined ultracentral lung cancer as the planning target volume (PTV) directly abutting or overlapping central structures, including the proximal bronchial tree, heart, and great vessels but not the esophagus. The Kaplan‐Meier method was used to estimate overall survival (OS), progression‐free survival (PFS) and local control (LC). Toxicity was scored per the CTCAE v4.03. Results: The median follow‐up time was 15 months, and the median OS was 15 months. The one‐ and two‐year OS rates were 87.5% and 76.6%, respectively. The one‐ and two‐year PFS rates were 71.1% and 64.0%, respectively. The one‐ and two‐year LC rates were 92.9% and 92.9%, respectively. The rate of grade 2 treatment‐related toxicities was 19.1%. There was no grade ≥ 3 treatment‐related toxicity. Conclusion: SABR of 60 Gy in eight fractions is feasible for ultracentral NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Magnetic resonance (MR) imaging for tumor staging and definition of tumor volumes on radiation treatment planning in nonsmall cell lung cancer: A prospective radiographic cohort study of single center clinical outcome.
- Author
-
Dan Zhao, Qiaoqiao Hu, Liping Qi, Juan Wang, Hao Wu, Guangying Zhu, Huiming Yu, Zhao, Dan, Hu, Qiaoqiao, Qi, Liping, Wang, Juan, Wu, Hao, Zhu, Guangying, and Yu, Huiming
- Published
- 2017
- Full Text
- View/download PDF
23. Variations of circulating endothelial progenitor cells and transforming growth factor-beta-1 (TGF-β1) during thoracic radiotherapy are predictive for radiation pneumonitis.
- Author
-
Yunfang Liu, Tingyi Xia, Wenjun Zhang, Yongjie Zhong, Luhua Zhang, Xuan Wang, Huiming Yu, Liu, Yunfang, Xia, Tingyi, Zhang, Wenjun, Zhong, Yongjie, Zhang, Luhua, Wang, Xuan, and Yu, Huiming
- Subjects
PROGENITOR cells ,RADIATION pneumonitis ,TRANSFORMING growth factors-beta ,RADIOTHERAPY ,SMALL cell lung cancer - Abstract
Background: The vascular endothelial cells are important targets of radiotherapy, which may be involved in the pathogenesis of radiation pneumonitis (RP). This study investigated the variations of circulating endothelial progenitor cells (EPCs) and transforming growth factor-beta-1 (TGF-β1) during three-dimensional conformal radiation therapy (3D-CRT) in patients with non-small-cell lung cancer (NSCLC) and analyzed the correlation between these variations with the occurrence of RP.Patients and Methods: From November 2008 to November 2009, eighty-four consecutive patients receiving 3D-CRT for stage III disease were evaluated prospectively. Circulating EPCs and TGF-β1 levels were measured at baseline, every 2 weeks during, and at the end of treatment. RP was evaluated prospectively at 6 weeks after 3D-CRT.Results: Thirty-eight patients (47.5%) experienced score 1 or more of RP. The baseline levels of EPCs and TGF-β1 were analyzed, no difference was found between patients with and without RP during and after 3D-CRT. By serial measurement of TGF-β1 and EPCs levels, we found that the mean levels of EPCs in the whole population remained stable during radiotherapy, but the mean levels of TGF-β1 increased slowly during radiotherapy. TGF-β1 and EPCs levels were all significantly higher at week 2, week 4 and week 6 in patients with RP than that in patients without RP, respectively. During the period of radiation treatment, TGF-β1 levels began to increase in the first 2 weeks and became significantly higher at week 6 (P < 0.01). EPCs levels also began to increase in the first 2 weeks and reached a peak at week 4. Using an ANOVA model for repeated-measures, we found significant associations between the levels of TGF-β1 and EPCs during the course of 3D-CRT and the risk of developing RP (P < 0.01). Most of the dosimetric factors showed a significant association with RP.Conclusion: Early variations of TGF-β1 and EPCs levels during 3D-CRT are significantly associated with the risk of RP. Variations of circulating TGF-β1 and EPCs levels during 3D-CRT may serve as independent predictive factors for RP.Trial Registration: Trials registration number: 20070618. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
24. Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer.
- Author
-
Zeng, Haiyan, Li, Rui, Hu, Chen, Qiu, Guoqin, Ge, Hong, Yu, Huiming, Zhang, Kaixian, Hu, Miaomiao, Zeng, Peng, Xiao, Dan, Miao, Chuanwang, Wei, Chuqing, Ni, Meng, Shen, Jingyi, Li, Hui, Yue, Jinbo, Lu, Heming, Fan, Bingjie, Zhu, Hui, and Hu, Xudong
- Published
- 2019
- Full Text
- View/download PDF
25. MicroRNA-708 suppresses the proliferation, migration, and invasion of human retinoblastoma cells by targeting RAP2B, a member of the RAS oncogene family.
- Author
-
Dai C, Yu H, Bai Q, Huang D, Li J, and Wang W
- Subjects
- Child, Humans, Apoptosis genetics, Cell Line, Tumor, Cell Movement genetics, Cell Proliferation genetics, Gene Expression Regulation, Neoplastic, Genes, ras, Neoplasm Invasiveness genetics, MicroRNAs metabolism, rap GTP-Binding Proteins genetics, rap GTP-Binding Proteins metabolism, Retinal Neoplasms genetics, Retinal Neoplasms pathology, Retinoblastoma genetics, Retinoblastoma pathology
- Abstract
Retinoblastoma generally affects children and causes permanent vision failure or even death. MicroRNAs (miRs) have recently gained much attention during recent years. The miR-708 acts as a tumor suppressor in several human cancers, but the former has not been functionally characterized in human retinoblastoma. The present study was designed to investigate the role of miR-708 in human retinoblastoma. The results showed that miR-708 is significantly (P<0.05) downregulated in retinoblastoma cell lines. MiR-708 overexpression significantly (P<0.05) inhibited retinoblastoma cell growth and proliferation by inducing apoptosis. Furthermore, retinoblastoma cells overexpressing miR-708 exhibited a markedly lower migratory rate and invasiveness compared to negative control cells. The bioinformatics and dual luciferase assay revealed a RAS oncogene family protein, RAP2B, which acts as the regulatory target and functional mediator of the molecular role of miR-708 in retinoblastoma. Together, the present study revealed the tumor suppressor role of miR-708 and pointed to the therapeutic implications of miR-708/RAP2B in the treatment of retinoblastoma.
- Published
- 2022
- Full Text
- View/download PDF
26. Celastrol promotes chondrocyte autophagy by regulating mTOR expression.
- Author
-
Dai S, Fan J, Zhang Y, Hao Z, Yu H, and Zhang Z
- Subjects
- Apoptosis, Autophagy, Pentacyclic Triterpenes, TOR Serine-Threonine Kinases genetics, Chondrocytes, Triterpenes pharmacology
- Published
- 2022
- Full Text
- View/download PDF
27. Evaluation of a Novel Left Ventricular Assist Device for Resuscitation in an Animal Model of Ventricular Fibrillation Cardiac Arrest.
- Author
-
Wang Z, Yu H, Yan S, Yan H, Chen D, Dai Y, Xu Q, Zeng Z, Zhang W, and Jin L
- Subjects
- Animals, Disease Models, Animal, Resuscitation, Swine, Ventricular Fibrillation therapy, Heart Arrest therapy, Heart-Assist Devices
- Abstract
We evaluated an independently developed novel percutaneous implantable left ventricular assist device for resuscitation in a pig model of ventricular fibrillation cardiac arrest. The model was established in 10 domestic pigs by blocking the anterior descending coronary artery with a balloon after anesthesia. With ventilator-assisted ventilation, the independently developed percutaneous implantable left ventricular assist device was inserted via the femoral artery to assist circulation. According to whether effective circulatory support was achieved, the pigs were randomly divided into an experimental group and a control group. The experimental group was subjected to insertion of the assist device and received continuous circulatory support. The control group underwent insertion of the assist device; however, it did not start it within 15 minutes. For all animals, if successful rescue was achieved (sinus rhythm restoration within 15 minutes and maintenance for over 5 minutes), circulatory support was stopped, and the arterial blockage was removed. If sinus rhythm was not restored within 15 minutes, electric defibrillation, adrenaline injection, and removal of the arterial blockage were performed, and circulatory support was provided until sinus rhythm recovered. A determination of failed rescue was made when sinus rhythm was not restored after 1 hour. All successfully rescued animals were fed for 1 week. There were no significant differences in baseline data between the groups. All animals underwent successful novel left ventricular assist device implantation through the femoral artery. The rescue rate was significantly higher in the experimental group than in the control group (80% vs. 0%, [Formula: see text]). All successfully rescued animals survived after 1 week of feeding, and no eating or movement abnormalities were observed. We conclude that this independently developed percutaneous implantable left ventricular assist device can be conveniently and rapidly implanted through the femoral artery and can maintain basic circulatory perfusion during resuscitation in an animal model of cardiac arrest.
- Published
- 2021
- Full Text
- View/download PDF
28. Liquiritigenin exerts the anti-cancer role in oral cancer via inducing autophagy-related apoptosis through PI3K/AKT/mTOR pathway inhibition in vitro and in vivo .
- Author
-
Ji Y, Hu W, Jin Y, Yu H, and Fang J
- Subjects
- Animals, Apoptosis drug effects, Cell Line, Tumor, Female, Humans, Mice, Mice, Inbred BALB C, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, TOR Serine-Threonine Kinases metabolism, Antineoplastic Agents pharmacology, Autophagy drug effects, Flavanones pharmacology, Mouth Neoplasms metabolism, Signal Transduction drug effects
- Abstract
Operative treatment on oral cancer greatly damages the chewing and language function of the patient, we aim to find better solution with fewer side effects. The anti-tumor effects of Liquiritigenin (LQ) have been explored in kinds of cancers, but not in oral cancer. In this study, our purpose is to reveal the effects of LQ on oral cancer and the associated mechanism.Cell proliferation was examined through 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and 5-Ethynyl-2'- deoxyuridine (EDU) staining. Cell apoptosis in cells and tissues were assessed by flow cytometry and terminal dexynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, respectively. Expressions of AKT and light chain 3 (LC3) were detected through Immunofluorescence. In addition, xenograft model was established by injecting the CAL-27 cells (2 × 10
6 ) subcutaneously into the right flanks of mice. Expression of Ki67 and Beclin1 in tissues was valued by Immunohistochemistry (IHC).We found that cell viability of CAL-27 and SCC-9 was effectively inhibited by LQ. Besides, obvious cell apoptosis and cell autophagy were induced by LQ. In addition, PI3K/AKT/mTOR pathway was sharply inactivated by LQ in oral cancer cells. Corresponding in vivo experiments demonstrated that tumor growth was largely restricted, cell apoptosis was augmented and autophagy was enhanced by LQ. What is more, phosphorylation of AKT in tumor tissues could also be inhibited by LQ. LQ inhibited the progression of oral cancer through inducing autophagy-associated apoptosis via PI3K/AKT/mTOR pathway inhibition, revealing a new possible scheme for the treatment of oral cancer.- Published
- 2021
- Full Text
- View/download PDF
29. Watertight 2-manifold 3D bone surface model reconstruction from CT images based on visual hyper-spherical mapping.
- Author
-
Yuan T, Zhang H, Liu H, Du J, Yu H, Wang Y, and Xu Y
- Subjects
- Algorithms, Imaging, Three-Dimensional, Tomography, X-Ray Computed
- Abstract
This paper proposes a general algorithm to reconstruct watertight 2-manifold 3D bone surface model from CT images based on visual hyper-spherical mapping. The reconstruction algorithm includes three main steps: two-step thresholding, initial watertight surface reconstruction and shape optimization. Firstly, volume sampling points of the target bone with given narrower threshold range are extracted by thresholding with combination of 3D morphology operation. Secondly, visible points near the bone's outer surface are extracted from its corresponding volume sampling points by hyper-spherical projection mapping method. Thirdly, implicit surface reconstruction algorithm is employed on the extracted visible surface points to obtain an initial watertight 3D bone surface model which is used as the deformation model in the following accurate bone surface model generation stage. Finally, the initial surface model is deformed according to the segmentation data with wider threshold range under given constraints in order to achieve an accurate watertight 3D bone surface model. Experiment and comparison results show that the proposed algorithm can reconstruct watertight 3D bone surface model from CT images, and local details of the bone surface can be restored accurately for the cases used in this paper.
- Published
- 2021
- Full Text
- View/download PDF
30. Long noncoding RNA FER1L4 regulates rheumatoid arthritis via targeting NLRC5.
- Author
-
Yu H, Ding C, Dai S, Sun J, Wang S, and Zhang Z
- Subjects
- Cell Proliferation, Cells, Cultured, Fibroblasts, Humans, Intracellular Signaling Peptides and Proteins, Synovial Membrane, Arthritis, Rheumatoid, RNA, Long Noncoding, Synoviocytes
- Abstract
Objectives: Rheumatoid arthritis (RA) is a systematic autoimmune disease that cardinally affects the joints and other organs. Many people all over the world are suffering from the disease and no effective treatment has been established. Fibroblast-like synoviocytes (FLSs) play a critical role in the occurrence and development of RA. Long non-coding RNA Fer-1-like protein 4 (FER1L4) has been reported to participate in various cancers as a tumour suppressor. However, its clinical significance and biological role in RA is completely unknown., Methods: RT-qPCR or FISH were used to examine the expression of FER1L4 NLRC5, FER1L4 and inflammatory cytokine levels in synovial tissues (STs) from patients with RA or RA FLSs. Western blot was applied to examine the expression of NLRC5 and inflammatory cytokine levels in synovial tissues (STs) from patients with RA or RA FLSs. BrdU staining and MTT assay were used to examine the cell proliferation ability. The methylation-specific PCR was performed to analyse the methylation levels., Results: The level of FER1L4 significantly reduced in STs and FLSs, whereas the nucleotide oligomerisation domain-like receptors 5 (NLRC5) levels were increased. Overexpression of FER1L4 can decreased the level of NLRC5 and inflammatory cytokine level. The FER1L4 gene promoter was significantly methylated in RA STs and FLSs. More importantly, treatment with methylation inhibitor 5-aza-2-deoxycytidine (5-azadC) inhibited hypermethylation of FER1L4 promoter and the expression of NLRC5., Conclusions: These results indicated that FER1L4 regulates RA via targeting NLRC5 potentially. Therefore, this study may provide a candidate therapeutic target for RA.
- Published
- 2020
31. [Application of Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Locally Advanced Non-small Cell Lung Cancer].
- Author
-
You J, Yang D, Li D, Jiang L, Yu R, Yu H, Xu B, Wang W, and Shi A
- Subjects
- Adult, Aged, 80 and over, Female, Humans, Male, Middle Aged, Radiotherapy, Intensity-Modulated adverse effects, Retrospective Studies, Safety, Survival Analysis, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Radiotherapy, Intensity-Modulated methods
- Abstract
Background: The standard treatment for locally advanced non-small cell lung cancer (NSCLC) is radiotherapy concurrent with chemotherapy, but the survival was not satisfied. With the development of intensity modulated radiotherapy, simultaneous integrated boost technique (SIB) becomes the research direction of locally advanced NSCLC. The aim of this study is to investigate the efficacy and safety of SIB intensity modulated radiotherapy technique for locally advanced NSCLC., Methods: We retrospectively reviewed the clinical data of locally advanced NSCLC who were treated with radiotherapy by SIB technique in Peking University Cancer Hospital from June 2015 to December 2018. Kaplan-Meier method was used for analysis., Results: Ninty-three patients were included in the analysis. After a median follow-up of 34.23 months, 3-year overall survival (OS), progression-free survival (PFS), local-recurrence free survival (LRFS) and metastasis free survival (MFS) rates were 53.0%, 37.0%, 50.5% and 50.5%, respectively. The incidence of grade ≥3 esophagitis was 5.4%. There were 2 (2.2%) patients experiencing grade ≥3 radiation-related pneumonia., Conclusions: Radiation with SIB intensity modulated radiotherapy technique is effective and safe for patients with locally advanced NSCLC.
- Published
- 2019
- Full Text
- View/download PDF
32. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
- Author
-
You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, and Zhu G
- Subjects
- Adult, Aged, Chemoradiotherapy adverse effects, Cisplatin adverse effects, Cisplatin therapeutic use, Disease-Free Survival, Dose-Response Relationship, Radiation, Etoposide adverse effects, Etoposide therapeutic use, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Male, Middle Aged, Radiotherapy Dosage, Safety, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma radiotherapy, Time Factors, Chemoradiotherapy methods, Lung Neoplasms pathology, Lung Neoplasms therapy, Radiotherapy, Intensity-Modulated adverse effects, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma therapy
- Abstract
Background: Twice-daily radiation concurrent with chemotherapy is one of the standard methods for limited-stage small cell lung cancer. The study was to evaluate the feasibility of chemotherapy concurrent with dose-escalating twice-daily radiotherapy by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) approach in patients with limited-stage small cell lung cancer., Methods: Patients with limited-stage small cell lung cancer were included, treated with twice-daily radiotherapy by SIB-IMRT concurrent with chemotherapy of etoposide plus cisplatin. Dose escalation was conducted by "classical" 3+3 methods with three patients enrolled in each dose level. The therapeutic gross tumor volume (GTV) was treated according to three consecutive dose levels i.e., 45 Gy at 1.5 Gy twice daily, 50 Gy at 1.67 Gy twice daily and 54 Gy at 1.8 Gy twice daily. The planning target volume (PTV) received a dose of 45 Gy delivered in 30 fractions of 1.5 Gy. The primary endpoints were acute toxicities. The secondary endpoints included overall survival (OS), progression-free survival (PFS) and loco-regional failure-free survival (LRFFS) at 1-year of follow-up., Results: Twenty men and six women were included. The median age was 52 (30-68) months. 12 patients experienced grade 2 acute esophagitis, and 1 patient developed grade 3 acute esophagitis. Only 3 patients developed Grade 2 pneumonitis. Grade 3 or higher radiation-related pneumonia was not observed. None died of treatment-related causes. With median follow-up of 11.2 months (3.2-36.2 months), 1-year OS, PFS and LRFFS were 89.0%, 51.0% and 85.0%, respectively., Conclusions: Dose escalation for twice-daily radiation concurrent with chemotherapy in LS-SCLC has been safely achieved up to 54 Gy for GTV using SIB-IMRT technique.
- Published
- 2017
- Full Text
- View/download PDF
33. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer].
- Author
-
You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, and Zhu G
- Subjects
- Adult, Aged, Chemoradiotherapy adverse effects, Cisplatin adverse effects, Disease-Free Survival, Dose-Response Relationship, Drug, Etoposide adverse effects, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Safety, Treatment Outcome, Young Adult, Chemoradiotherapy methods, Cisplatin therapeutic use, Etoposide therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma radiotherapy
- Abstract
Background: Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer., Methods: Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible. The patients underwent thoracic radiotherapy (45 Gy, 1.5 Gy bid, 30 fractions for 3 weeks) delivered concurrently with etoposide (100 mg/m2 iv, days 1-3) and cisplatin dose escalating from the two levels ( 70 mg/m2 and 75 mg/m2 on d1). The primary endpoints were hematologic toxicities during treatment. The secondary endpoints were non-hematologic toxicities, overall survival (OS) and progression-free survival (PFS). According to Common Terminology Criteria for Adverse Events 4.0 (CTC-AE 4.0), maximum tolerant dosage (MTD) was defined as the highest safely tolerated dose at which no more than one patient out of six experiences dose-limiting toxicity (Grades 4 hematologic), with the next higher dose having at least two out of six patients experience dose-limiting toxicity., Results: From January 2013 to August 2016, 20 patients were enrolled in this study. The median age was 49.5 (30-68). After the first 6 patients were enrolled in Arm 1 (70 mg/m2 on d1), one patient had Grade 4 neutropenia. Another 14 patients were enrolled in Arm 2 (75 mg/m2 on d1), one patient had Grade 4 neutropenia. The MTD was determined to be etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). 4 patients had ≥Grade 3 neutropenia and 1 patients had ≥Grade 3 acute esophagitis in Arm 1. 10 patients had ≥Grade 3 neutropenia and no patient had ≥Grade 3 acute esophagitis in Arm 2. All patients with a median follow-up time was 9.0 months, median OS and PFS were not achieved, 1-year OS and PFS were 91% and 61%, respectively., Conclusions: The MTD of RT with concurrent chemotherapy of EP regimen for patients with LS-SCLC was etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). .
- Published
- 2017
- Full Text
- View/download PDF
34. MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
- Author
-
Yue X, Cao D, Lan F, Pan Q, Xia T, and Yu H
- Subjects
- Animals, Apoptosis, Cell Cycle Proteins genetics, Cell Proliferation, Gene Expression Regulation, Neoplastic, Glioma genetics, Glioma metabolism, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Septins genetics, Survival Rate, Tumor Cells, Cultured, Wnt Proteins genetics, Xenograft Model Antitumor Assays, beta Catenin genetics, Cell Cycle Proteins metabolism, Glioma pathology, MicroRNAs genetics, Septins metabolism, Wnt Proteins metabolism, beta Catenin metabolism
- Abstract
Background: miR-301a is frequently dysregulated and specific to human tumors, playing a critical role in tumorigenesis; however, the exact functions and regulatory mechanisms of miR-301a in glioma cells remain largely unknown. Herein, we show that miR-301a activated by the Wnt/β-catenin pathway promoted the invasion of glioma cells by directly targeting SEPT7., Methods: Biochemical, luciferase reporter, and hromatin immunoprecipitation PCR assays characterized the function and regulatory mechanisms of miR-301a in glioma invasion., Results: Initially, we detected the expression of miR-301a in glioma tissues and identified that miR-301a had increased, with ascending grades of the tumor. Furthermore, high levels of miR-301a were associated with a poorer prognosis in glioma patients. It is important to note that the Wnt/β-catenin/TCF4 pathway enhanced miR-301a expression by binding to the promoter region. To determine the oncogenic functions of miR-301a in glioma, SEPT7 was supported as the direct target gene. In addition, the Wnt/β-catenin pathway repressed SEPT7 expression, which was dependent on miR-301a in glioma cells. Finally, miR-301a was activated by Wnt/β-catenin and then promoted invasion of glioma cells by inhibiting the expression of SEPT7 in vitro and in vivo., Conclusions: Our findings revealed the mechanism of action for miR-301a in tumor cell invasion. Moreover, the Wnt/miR-301a/SEPT7 signaling axis might be a novel target in treating glioma., (© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
35. Efficacy of the smaller target volume for stage III non-small cell lung cancer treated with intensity-modulated radiotherapy.
- Author
-
Liang X, Yu H, Yu R, Xu G, and Zhu G
- Abstract
The present study reports the local recurrence, distant metastasis, progression-free survival, overall survival and radiation toxicity between two arms of stage III non-small cell lung cancer (NSCLC) treated with intensity-modulated radiotherapy (IMRT); one arm with clinical target volume (CTV) and the other without CTV. The two arms of local recurrence, distant metastasis, progression-free survival, overall survival, grade 3-4 radiation esophagitis and hematological toxicity had no statistical significance. However, the grade 3-4 radiation pneumonia rate of the group without CTV was significantly decreased. This supports the concept that stage III NSCLC treated with IMRT, which omitted CTV, can reduce the occurrence of radiation pneumonia. The aim of the present study was to analyze the feasibility of the smaller target volume for stage III NSCLC treated with IMRT. Data from 105 patients with stage III NSCLC who were hospitalized and received IMRT between January 1, 2008 and November 30, 2012 were retrospectively analyzed. A total of 55 cases were irradiated with target volume without CTV and 50 cases were irradiated with CTV. Dose prescription was 100% PTV at 54-63 Gy/27-35 F/5.4-7 weeks. The two arms of the patient characteristics and treatment deliveries had no statistical significance. The two arms of the patients were compared for local recurrence, distant metastasis, progression-free survival, overall survival and radiation-related toxicity. In the arms without and with CTV, the local relapse and distant metastases rates were 32.7 and 32.0% (P=1.000) and 56.4 and 48.0% (P=0.946), respectively. The median progression-free survival time for the two arms was 9 months (P=0.619). The 1-, 2- and 3-year survival rates of the arms without and with CTV were 74.5, 43.6 and 23.6%, and 70.0, 46.0 and 20.0% (P=0.956), respectively. In the two arms, grade 3-4 radiation esophagitis and hematological toxicity had no statistical significance. However, in the arm without CTV, grade 3-4 radiation pneumonia was only 5.5%, compared with 18.0% in the arm with CTV (P=0.044). In conclusion, the smaller target volume for stage III NSCLC treated with IMRT was feasible.
- Published
- 2015
- Full Text
- View/download PDF
36. Variations of circulating endothelial progenitor cells and transforming growth factor-beta-1 (TGF-β1) during thoracic radiotherapy are predictive for radiation pneumonitis.
- Author
-
Liu Y, Xia T, Zhang W, Zhong Y, Zhang L, Wang X, and Yu H
- Subjects
- Adult, Aged, Carcinoma, Non-Small-Cell Lung blood, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Humans, Lung Neoplasms blood, Male, Middle Aged, Radiotherapy, Conformal adverse effects, Carcinoma, Non-Small-Cell Lung radiotherapy, Cell Movement, Endothelial Progenitor Cells cytology, Lung Neoplasms radiotherapy, Radiation Pneumonitis blood, Transforming Growth Factor beta1 blood
- Abstract
Background: The vascular endothelial cells are important targets of radiotherapy, which may be involved in the pathogenesis of radiation pneumonitis (RP). This study investigated the variations of circulating endothelial progenitor cells (EPCs) and transforming growth factor-beta-1 (TGF-β1) during three-dimensional conformal radiation therapy (3D-CRT) in patients with non-small-cell lung cancer (NSCLC) and analyzed the correlation between these variations with the occurrence of RP., Patients and Methods: From November 2008 to November 2009, eighty-four consecutive patients receiving 3D-CRT for stage III disease were evaluated prospectively. Circulating EPCs and TGF-β1 levels were measured at baseline, every 2 weeks during, and at the end of treatment. RP was evaluated prospectively at 6 weeks after 3D-CRT., Results: Thirty-eight patients (47.5%) experienced score 1 or more of RP. The baseline levels of EPCs and TGF-β1 were analyzed, no difference was found between patients with and without RP during and after 3D-CRT. By serial measurement of TGF-β1 and EPCs levels, we found that the mean levels of EPCs in the whole population remained stable during radiotherapy, but the mean levels of TGF-β1 increased slowly during radiotherapy. TGF-β1 and EPCs levels were all significantly higher at week 2, week 4 and week 6 in patients with RP than that in patients without RP, respectively. During the period of radiation treatment, TGF-β1 levels began to increase in the first 2 weeks and became significantly higher at week 6 (P < 0.01). EPCs levels also began to increase in the first 2 weeks and reached a peak at week 4. Using an ANOVA model for repeated-measures, we found significant associations between the levels of TGF-β1 and EPCs during the course of 3D-CRT and the risk of developing RP (P < 0.01). Most of the dosimetric factors showed a significant association with RP., Conclusion: Early variations of TGF-β1 and EPCs levels during 3D-CRT are significantly associated with the risk of RP. Variations of circulating TGF-β1 and EPCs levels during 3D-CRT may serve as independent predictive factors for RP., Trial Registration: Trials registration number: 20070618.
- Published
- 2013
- Full Text
- View/download PDF
37. Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial.
- Author
-
Liu Y, Zhu G, Han L, Liu J, Ma T, and Yu H
- Abstract
Objective. Oxaliplatin-induced peripheral neurotoxicity continues to be a kind of frequent dose-limiting toxicity for many cancer patients. This study evaluated the preventive effects of Guilongtongluofang on peripheral neurotoxicity induced by oxaliplatin in patients with colorectal tumor. Patients and Methods. From May 2007 to May 2011, we conducted a randomized, double-blind, placebo-controlled trial. 120 patients of colorectal cancer treated with adjuvant oxaliplatin-based chemotherapy were randomly enrolled into the trial group and the control group. The trial group received Guilongtongluofang (at a dose of 200 mL once a day) from 3 days prior to chemotherapy. The control group received a placebo from 3 days prior to chemotherapy. Every 2-week cycle, neurotoxicity was evaluated using numeric rating scale for pain intensity and experienced relief. The primary endpoint was efficacy measurement which included oxaliplatin-induced neurotoxicity and tumor response. The differences of side effects between the two groups were also analyzed. Results. The percentage of grades 1-2 neurotoxicity was significantly lower in the trial group than that in the control group (13.3% versus 20.0%; P < 0.05) after two cycles of treatment. The difference of the percentage of neurotoxicity between the two groups was significant after six cycles (51.7% versus 70.0%; P < 0.05). Significant difference for the mean time to the development of grade 1+ neurotoxicity was found between the two groups (9.4 w in the trial group versus 6.5 w in the control group, P < 0.05). The cumulative incidence of grade 1 or more sensory neurotoxicity was significantly lower in the trial group than that in the control group (P < 0.05). No significant differences of tumor response rate were found between the two groups the trial group and the control group. No significant difference was found between the trial group and the control group (all P > 0.05). Conclusion. This study provides evidence that Guilongtongluofang is a promising drug for the prevention of oxaliplatin-induced neurotoxicity in patients with colorectal cancer, and it does not reduce the efficacy of oxaliplatin.
- Published
- 2013
- Full Text
- View/download PDF
38. A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms.
- Author
-
Sun C, Yu H, Wang X, and Han J
- Abstract
The inhibitory effects of magnetic fields (MFs) on tumor cell proliferation in vitro and in vivo have been reported in previous studies. However, the effects of MFs in the treatment of cancer have not been described in clinical trials. We investigated the effects of 420 r/min, 0.4-T extremely low-frequency MFs (ELF-MFs) on the survival and palliation of general symptoms in 13 advanced non-small cell lung cancer (NSCLC) patients. Toxicity and side-effects were assessed according to WHO criteria. The treatment area included the primary tumor site, metastatic sites and metastatic lymph nodes. Additionally, the patients were treated 2 h per day, 5 days per week for 6-10 weeks. The changes in general symptoms were analyzed during ELF-MF treatment and 2 weeks after the completion of therapy. Results of physical examination, routine analysis of blood, ECG and liver function, biochemical and kidney function tests were evaluated before and following treatment. All 13 patients were followed up by outpatient service or telephone interview. Our results demonstrated that decreased pleural effusion, remission of shortness of breath, relief of cancer pain, increased appetite, improved physical strength, regular bowel movement and better sleep quality was detected in 2 (15.4%), 5 (38.5%), 5 (38.5%), 6 (46.2%), 9 (69.2%), 1 (7.7%) and 2 (15.4%) patients, respectively. However, the palliation of symptoms in 2 (15.4%) patients was observed during therapy and disappeared at treatment termination. No severe toxicity or side-effects were detected in our trial. The median survival was 6.0 months (95% CI, 1.0-11.0). The 1- and 2-year survival rates were 31.7 and 15.9%, respectively. This study is the first to describe survival and palliation of general symptoms in advanced NSCLC patients treated with ELF-MFs. As an effective, well-tolerated and safe treatment choice, ELF-MFs may prolong survival and improve general symptoms of advanced NSCLC patients. However, this treatment strategy requires further research.
- Published
- 2012
- Full Text
- View/download PDF
39. Giant cell tumor of the tendon sheath: A rare case in the left knee of a 15-year-old boy.
- Author
-
Sun C, Sheng W, Yu H, and Han J
- Abstract
Localized forms of giant cell tumors are defined as giant cell tumors of the tendon sheath (GCTTS). GCTTS arises from the synovium of a joint, bursa or tendon sheath, and 85% of the tumors occur in the fingers. GCTTS in the knee is extremely rare. We report an unusual case of a 15-year-old boy who presented with an occult growing swelling and a 2-month history of infra-patellar pain in the left knee. Magnetic resonance imaging (MRI) demonstrated a well-circumscribed soft tissue mass in the infra-patellar fat pad posterior to the patella tendon. Excision biopsy was performed by surgical removal. Histopathological examination revealed that it was GCTTS. During the follow-up period, his recovery was propitious and there was no recurrence. Owing to its few and non-specific symptoms, and local recurrence varying from 9 to 44%, its proper, early diagnosis and appropriate treatment is necessary. The purpose for which we report the case is to emphasize the possibility of GCTTS where there is a mass with non-specific symptoms such as infra-patellar pain of the knee, and to avoid misdiagnosis where possible.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.